Connecticut Wealth Management LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connecticut Wealth Management LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 996 shares of the biopharmaceutical company’s stock after selling 187 shares during the period. Connecticut Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $875,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Meyer Handelman Co. raised its stake in shares of Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after buying an additional 435 shares during the last quarter. Stifel Financial Corp lifted its holdings in Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after acquiring an additional 3,385 shares during the period. LPL Financial LLC boosted its position in Regeneron Pharmaceuticals by 9.3% in the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after purchasing an additional 1,221 shares during the period. Finally, Monetary Management Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 4.8% in the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock valued at $901,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $19.39 during trading hours on Friday, reaching $957.00. The company had a trading volume of 547,373 shares, compared to its average volume of 509,442. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 6.40. The company has a market capitalization of $105.04 billion, a price-to-earnings ratio of 28.27, a PEG ratio of 2.74 and a beta of 0.17. The stock has a fifty day moving average of $943.75 and a 200-day moving average of $897.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the prior year, the business earned $10.96 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Truist Financial restated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Insider Activity

In related news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,095 shares of company stock valued at $9,664,476. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.